Search Results 701-710 of 18359 for alopecia
03 (except alopecia or peripheral neuropathy that may be Grade 2 or less) at the time of randomization. Patients with Grade 2 neuropathy are eligible but ...
Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade ...
0) ≤ Grade 1, or to the levels dictated in the eligibility criteria with the exception of alopecia. Patient with history of confirmed progressive ...
03) except for alopecia, Grade 2 sensory neurotoxicity, or any other toxicity that in the opinion of the Investigator does not affect the assessment of ...
... alopecia or toxicities that are stable and well-controlled and there is agreement to allow by the investigator and sponsor; Subject unable to receive both ...
Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less, except for alopecia,; Participants with ...
Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 ...
... alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled. For ...
Patient with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not ...
... alopecia and fatigue; No craniotomy within 28 days of registration. Not pregnant and not nursing. A female of childbearing potential is a sexually mature ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!